Lobbying

Advanced Medical Technology Assn's latest lobbying report covers Q2 2026, at $971K. The four quarters Q3 2025–Q2 2026 total $3.9M. Its first report covers Q4 2022; the issues it reports most are Budget/Appropriations and Health Issues.

Advanced Medical Technology Assn

Latest quarter
$971K
Q2 2026 · 1 reports
Last 12 months
$3.9M
Last 4 quarters
vs last quarter
−11.7%
Q2 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Advanced Medical Technology Assn lobbying by quarter
Advanced Medical Technology Assn lobbying by quarter
QuarterAmountReports
Q4 2022$750K1
Q1 2023$840K1
Q2 2023$700K1
Q3 2023$680K1
Q4 2023$680K1
Q1 2024$1M1
Q2 2024$880K1
Q3 2024$960K1
Q4 2024$940K1
Q1 2025$1M1
Q2 2025$950K1
Q3 2025$860K1
Q4 2025$942K1
Q1 2026$1.1M1
Q2 2026$971K1

Policy issues the reports name

  • Budget and appropriations15 reports
  • Health issues15 reports
  • Medicare and Medicaid15 reports
  • Small business15 reports
  • Taxation15 reports
  • Trade15 reports

A report that names several issues counts once for each.

Who was lobbied

  • Centers For Disease Control & Prevention (CDC)15 reports
  • Centers For Medicare and Medicaid Services (CMS)15 reports
  • Commerce, Dept of (DOC)15 reports
  • Environmental Protection Agency (EPA)15 reports
  • Food & Drug Administration (FDA)15 reports
  • Health & Human Services, Dept of (HHS)15 reports
  • HOUSE OF REPRESENTATIVES15 reports
  • Natl Security Council (NSC)15 reports
  • Office of Management & Budget (OMB)15 reports
  • SENATE15 reports
  • State, Dept of (DOS)15 reports
  • U.S. Trade Representative (USTR)15 reports
  • White House Office15 reports
  • Treasury, Dept of5 reports

Firms it paid

Firm
In-houseAdvanced Medical Technology Assn$13.3M15 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
07/20for Q2In-house$971K
04/20for Q1In-house$1.1M
01/20for Q4 2025In-house$942K
25/10/17for Q3 2025In-house$860K
25/07/17for Q2 2025In-house$950K
25/04/21for Q1 2025In-house$1M
25/01/17for Q4 2024In-house$940K
24/10/21for Q3 2024In-house$960K
24/07/19for Q2 2024In-house$880K
24/04/20for Q1 2024In-house$1M
24/01/19for Q4 2023In-house$680K
23/10/20for Q3 2023In-house$680K
23/07/20for Q2 2023In-house$700K
23/04/20for Q1 2023In-house$840K
23/01/20for Q4 2022In-house$750K